PF4-dependent P-selectin expression assay in comparison to the heparin-induced platelet activation assay for the diagnosis of heparin-induced thrombocytopenia
Research article published in Transfusion (2025)
Abstract
BACKGROUND: Heparin-induced thrombocytopenia (HIT) is a severe complication characterized by thrombocytopenia and thrombosis. The presence of antibodies against heparin/platelet factor 4 (PF4) complexes is a key indicator for HIT. Diagnostic laboratory testing generally includes detection of anti-heparin/PF4 and/or functional testing such as the heparin-induced platelet activation assay (HIPAA). However, current functional tests are time-consuming and require specific technical skills. The PF4-dependent P-selectin expression assay (PEA) is a flow cytometry-based test that evaluates activation of donor platelets in the presence of HIT patient serum. METHODS: We conducted the PEA with 23 patient sera that were positive in both the anti-PF4/heparin enzyme-linked immunosorbent assay (ELISA) and HIPAA and 26 sera that tested negative in the anti-PF4/heparin ELISA. We next compared the PEA to the HIPAA using a retrospective clinical cohort of 195 sera of suspected HIT patients and tested the reproducibility of the PEA. RESULTS: The PEA was found to have a sensitivity of 73.9% and a specificity of 73.1% compared to the HIPAA. In our retrospective clinical cohort, we found that 74.4% (145 out of 195 samples) had identical results in both the HIPAA and PEA, with a specificity of 64.94% and sensitivity of 80.51% for the PEA compared to the HIPAA. Reproducibility testing of the PEA across three independent runs demonstrated consistent results in 83.3% (30 out of 36 samples). DISCUSSION: These findings suggest that the PEA is a promising functional test for HIT laboratory diagnostics based on the relatively high sensitivity; however, further studies are needed to validate its clinical applicability.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Resumen
Peer-reviewed clinical and outcomes research relevant to anticoagulation, leech therapy, and microsurgical flap management. Indexed in PubMed and verified against the NCBI record.
Por qué esto importa para la hirudoterapia
Este estudio de precisión diagnóstica comparó un ensayo de expresión de P-selectina dependiente de PF4 mediante citometría de flujo (PEA) frente al ensayo establecido de activación plaquetaria inducida por heparin (HIPAA) para el diagnóstico de la trombocitopenia inducida por heparin, informando en una cohorte retrospectiva de 195 sueros con sospecha de HIT que ambas pruebas concordaron en el 74.4% de las muestras, mostrando el PEA una sensibilidad del 80.51% y una especificidad del 64.94% frente al HIPAA, y los autores concluyeron que se trata de una prueba funcional prometedora pero aún no validada. Para la hirudoterapia, esto constituye el contexto del campo de la HIT: un diagnóstico de HIT mejor y más rápido es fundamental precisamente porque la HIT confirmada exige una anticoagulación sin heparin, el nicho clínico que los inhibidores directos de la trombina (DTI), como la hirudin derivada de sanguijuelas, fueron desarrollados para cubrir. Advertencia: este es un estudio de comparación de métodos de laboratorio frente a un estándar de referencia imperfecto, los autores señalan la necesidad de una mayor validación y no estudia la terapia con sanguijuelas.
Citación
PF4-dependent P-selectin expression assay in comparison to the heparin-induced platelet activation assay for the diagnosis of heparin-induced thrombocytopenia.
Meier et al. · Transfusion, 2025
Contexto clínico relacionado
Explore cómo esta investigación se conecta con la práctica clínica
Añadido a la biblioteca ASH: May 28, 2026 · Última actualización del sitio: June 18, 2026